Nipocalimab improved fatigue by week 2 in patients, supporting its potential as a fast-acting, patient-centered therapy, says Irina Murakhovskaya, MD. Since sickle cell disease trial criteria exclude ...
AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...
As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...
On National HIV Testing Day, getting tested remains a gateway to prevention and treatment, but improving access alone is not enough. Expanding access to PrEP, PEP, pharmacists, long-acting therapies, ...
CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...
National health spending is forecast to approach $9 trillion by 2034, increasing faster than GDP and consuming 20.6% of the ...
Recent data from the National Cancer Institute (NCI) suggest that the number of people in the US diagnosed with diffuse large ...
From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...
Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative ...
Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...
New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results